- Home
- RMBI vs PEPG Comparison
RMBI vs PEPG Comparison
Compare RMBI & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- PEPG
- Stock Information
- Founded
- RMBI 1887
- PEPG 2018
- Country
- RMBI United States
- PEPG United States
- Employees
- RMBI N/A
- PEPG N/A
- Industry
- RMBI Major Banks
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- PEPG Health Care
- Exchange
- RMBI Nasdaq
- PEPG Nasdaq
- Market Cap
- RMBI 149.2M
- PEPG 147.0M
- IPO Year
- RMBI 2019
- PEPG 2022
- Fundamental
- Price
- RMBI $14.70
- PEPG $4.30
- Analyst Decision
- RMBI
- PEPG Buy
- Analyst Count
- RMBI 0
- PEPG 3
- Target Price
- RMBI N/A
- PEPG $14.67
- AVG Volume (30 Days)
- RMBI 19.9K
- PEPG 215.7K
- Earning Date
- RMBI 01-23-2025
- PEPG 11-07-2024
- Dividend Yield
- RMBI 3.80%
- PEPG N/A
- EPS Growth
- RMBI N/A
- PEPG N/A
- EPS
- RMBI 0.87
- PEPG N/A
- Revenue
- RMBI $42,258,740.00
- PEPG N/A
- Revenue This Year
- RMBI N/A
- PEPG N/A
- Revenue Next Year
- RMBI N/A
- PEPG N/A
- P/E Ratio
- RMBI $16.95
- PEPG N/A
- Revenue Growth
- RMBI N/A
- PEPG N/A
- 52 Week Low
- RMBI $10.11
- PEPG $2.90
- 52 Week High
- RMBI $15.15
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- RMBI 66.67
- PEPG 33.61
- Support Level
- RMBI $14.55
- PEPG $2.90
- Resistance Level
- RMBI $15.06
- PEPG $5.72
- Average True Range (ATR)
- RMBI 0.35
- PEPG 0.79
- MACD
- RMBI -0.04
- PEPG -0.01
- Stochastic Oscillator
- RMBI 47.37
- PEPG 35.44
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.